aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update
Globe Newswire•05/11/2026•16:01 ET
0
Key Highlights
- ➤FDA aligned on Phase 3 efzofitimod protocol using FVC as primary endpoint
- ➤aTyr prioritizes strategic partnerships to advance efzofitimod’s Phase 3 study
- ➤Cash position $50.3 million, supporting operations into late 2028
- ➤EFZO-CONNECT Phase 2 enrollment completed; full results expected Q2 2027
- ➤Q3 net loss $18.3 million versus $25.7 million year earlier
Expert Statements
Sanjay S. Shukla, President and Chief Executive Officer of aTyr
“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need”
Sanjay S. Shukla, President and Chief Executive Officer of aTyr
“We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships.”
Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated.
Company to prioritize strategic partnerships to advance Phase 3 study of efzofitimod in pulmonary sarcoidosis.
Get started
Create a free account to read the full story.